Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos; Meletios A Dimopoulos; Michèle Cavo; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lúcio; Zsolt Nagy; Polina Kaplan; Luděk Pour; Mark Cook; Sebastian Grosicki; Andre H Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung‐Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Christopher Chiu; Jianping Wang; Robin Carson; Wendy Crist; William Deraedt; Huong Nguyen; Ming Qi; Jesús F. San Miguel

doi:10.1056/nejmoa1714678

Abstract

1 min read

Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. The daratumumab-containing regimen was associated with more grade 3 or 4 infections. (Funded by Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479 .).

Related publications

Article2021

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva, Shaji Kumar, Meletios A Dimopoulos, Thierry Façon, María‐Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michèle Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis

Article2023

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen,

Article2014

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Monika Engelhardt, Evangelos Terpos, Martina Kleber, Francesca Gay, Ralph Wäsch, Gareth J. Morgan, Michèle Cavo, Niels W.C.J. van de Donk, Andreas Beilhack, Benedetto Bruno, Hans Erik Johnsen, Roman Hájek, Christoph Driessen, Heinz Ludwig, Meral Beksaç, Mario Boccadoro, Christian Straka, S. Brighen, Martin Gramatzki, Alessandra Larocca, H M Lokhorst, Valeria Magarotto, Fortunato Morabito, ,

Article2019

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Façon, Jae Hoon Lee, Philippe Moreau, Rubén Niesvizky, Meletios A Dimopoulos, Roman Hájek, Luděk Pour, Artur Jurczyszyn, Lugui Qiu, Zandra Klippel, Anita Zahlten‐Kumeli, Muhtarjan Osman, Bruno Paiva, Jesús F. San Miguel

Article2011

An Overview of the VISTA Trial: Newly Diagnosed, Untreated Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation

Ivan Špıčka, MV Mateos, Katherine Redman, Meletios A Dimopoulos, PG Richardson